Transcription of DRUG NAME: Bleomycin
{{id}} {{{paragraph}}}
Bleomycin BC Cancer Agency Cancer drug Manual Page 1 of 10 Bleomycin Developed: September 1994 Revised: 1 May 2007 Limited Revision: 1 March 2009, 1 June 2013, 1 December 2014 drug NAME: Bleomycin SYNONYM(S): NSC-125066;1 BLM ; Bleo COMMON TRADE NAME(S): BLENOXANE , generic available CLASSIFICATION: Antitumour antibiotic Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Bleomycin causes DNA strand scission through formation of an intermediate metal complex requiring a metal ion cofactor such as copper or This action results in inhibition of DNA synthesis, and to a lesser degree, in inhibition of RNA and protein The drug is cell-cycle specific for G phase, M-phase and S PHARMACOKINETICS: Interpatient variability no information found Distribution mainly in the skin, lungs, kidneys, peritoneum and lymphatics cross blood brain barrier?
The drug is cell-cycle specific for G phase, M-phase and S phase. 1. PHARMACOKINETICS: ... Discontinuation of therapy due to these toxicities occurs in about 2% of patients. 6. Febrile reactions. are seen in 50% of patients treated with bleomycin given IV and in …
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}